CSRM617 is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2), a key regulator of the androgen receptor (AR), and directly binds to the OC2-HOX domain (Kd = 7.43 μM in SPR assays); it induces apoptosis by cleaving Caspase-3 and PARP; it shows good tolerability in mouse models of prostate cancer.